Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healthy Male Participants

NCT02123953 | Completed Phase 1

• 2 other identifiers: TAK-438/CPH-002U1111-1153-6907
• Study Type: interventional
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study was to evaluate the safety and pharmacokinetics of TAK-438 following multiple oral doses to healthy adult Japanese male participants

Conditions

Dose Finding Study

Keywords

Drug therapy

Outcome Measures

Primary Outcomes (19)

• Number of Participants With Adverse Events (AE)

  An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it did not necessarily have to have a causal relationship with this treatment. The different categories of intensity (severity) were characterized as follows: Mild: The AE was transient and easily tolerated by the participant. Moderate: The AE caused the participant discomfort and interrupted the participant's usual activities. Severe: The AE caused considerable interference with the participant's usual activities.

  Day 1 to Day 15

• Number of Participants With Potentially Clinically Significant Vital Sign Findings

  Vital signs included blood pressure, pulse, respiratory rate, and body temperature (armpit).

  Day 1 to Day 15

• Number of Participants With Potentially Clinically Significant Changes in Body Weight

  Day 1 to Day 15

• Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings

  The investigator or the subinvestigator interpreted the ECG using 1 of the following categories: "within normal limits", "abnormal but not clinically significant", or "abnormal and clinically significant". The time that the ECG was performed was recorded. The following parameters were recorded from the participant's ECG trace: heart rate, RR interval, PR interval, QT interval, QRS duration, and QTc interval.

  Day 1 to Day 15

• Number of Participants With Potentially Clinically Significant Laboratory Evaluation Findings

  Laboratory tests for hematology, biochemistry, and urinalysis were be performed.

  Day 1 to Day 15

• AUC(0-tau): Area Under the Plasma Concentration-time Curve from Time 0 to Time tau Over the Dosing Interval for TAK-438F and TAK-438F metabolites M-I and M-II, M-III and M-IV-Sul

  AUC(0-tau) is a measure of the area under the plasma concentration-time curve from the time 0 to time tau over a dosing interval, where tau is the length of the dosing interval, 24 hours, calculated using the linear trapezoidal rule.

  Days 1 to 7 predose, Days 1 and 7 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16 hours post- dose, and Day 7 24 hours post-dose

• AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-438F and TAK-438F metabolites M-I and M-II, M-III and M-IV-Sul

  AUC(0-tlqc) is a measure of the area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration, calculated using the linear trapezoidal rule.

  Days 1 to 7 predose, Days 1 and 7 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16 hours post- dose, and Day 7 24 hours post-dose

• AUMC(0-tlqc): Area Under the First Moment Plasma Concentration-time Curve from Time 0 (t1) to Time of the Last Quantifiable Concentration (tlqc) for TAK-438F and TAK-438F metabolites M-I and M-II, M-III and M-IV-Sul

  AUMC(0-tlqc) is a measure of the area under the first moment plasma concentration-time curve from time 0 to time of the last quantifiable concentration (tlqc), calculated using the linear trapezoidal rule.

  Days 1 to 7 predose, Days 1 and 7 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16 hours post- dose, and Day 7 24 hours post-dose

• MRT(0-tlqc): Mean Residence Time from Time 0 (t1) to Time of the Last Quantifiable Concentration (tlqc) for TAK-438F and TAK-438F metabolites M-I and M-II, M-III and M-IV-Sul

  MRT(0-tlqc) is a measure of the mean residence time from time 0 to time of the last quantifiable concentration (tlqc) calculated as MRT(0-tlqc)=AUMC(0-tlqc)/AUC(0-tlqc).

  Days 1 to 7 predose, Days 1 and 7 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16 hours post- dose, and Day 7 24 hours post-dose

• Cmax: Maximum Observed Plasma Concentration for TAK-438F and TAK-438F metabolites M-I and M-II, M-III and M-IV-Sul

  Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

  Days 1 to 7 predose, Days 1 and 7 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16 hours post- dose, and Day 7 24 hours post-dose

• Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438F and TAK-438F metabolites M-I and M-II, M-III and M-IV-Sul

  Time to reach the maximum plasma concentration (Tmax), equal to time (hours) to Cmax.

  Days 1 to 7 predose, Days 1 and 7 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16 hours post- dose, and Day 7 24 hours post-dose

• AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F and TAK-438F metabolites M-I and M-II, M-III and M-IV-Sul

  AUC(0-inf) is a measure of the area under the plasma concentration-time curve from time 0 to infinity.

  Days 1 to 7 predose, Days 1 and 7 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16 hours post- dose, and Day 7 24 hours post-dose

• Terminal Elimination Rate Constant (λz) for TAK-438F and TAK-438F metabolites M-I and M-II, M-III and M-IV-Sul

  Terminal elimination rate constant (λz) is the rate at which drugs are eliminated from the body.

  Days 1 to 7 predose, Days 1 and 7 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16 hours post- dose, and Day 7 24 hours post-dose

• Terminal Elimination Half-life (T1/2) for TAK-438F and TAK-438F metabolites M-I and M-II, M-III and M-IV-Sul

  Terminal Phase Elimination Half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.

  Days 1 to 7 predose, Days 1 and 7 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16 hours post- dose, and Day 7 24 hours post-dose

• Apparent Clearance (CL/F) for TAK-438F

  CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC(0-24), expressed in L/hr.

  Days 1 to 7 predose, Days 1 and 7 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16 hours post- dose, and Day 7 24 hours post-dose

• Apparent Volume of Distribution (Vz/F) for TAK-438F

  Vz/F is the distribution of a drug between plasma and the rest of the body following oral administration, calculated as CL/F divided by λz.

  Days 1 to 7 predose, Days 1 and 7 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16 hours post- dose, and Day 7 24 hours post-dose

• AUMC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F and TAK-438F metabolites M-I and M-II, M-III and M-IV-Sul

  AUMC(0-inf) is a measure of the area under the first moment plasma concentration-time curve from time 0 to infinity.

  Days 1 to 7 predose, Days 1 and 7 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16 hours post- dose, and Day 7 24 hours post-dose

• MRT: Mean Residence Time for TAK-438F and TAK-438F metabolites M-I and M-II, M-III and M-IV-Sul

  Mean residence time, calculated as MRT=AUMC(0-inf)/AUC(0-inf)

  Days 1 to 7 predose, Days 1 and 7 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16 hours post- dose, and Day 7 24 hours post-dose

• Cumulative Urinary Excretion Ratio for TAK-438F and TAK-438F metabolites M-I and M-II, M-III and M-IV-Sul

  The cumulative urinary excretion ratio is defined as the percentage of the dose excreted in the urine.

  Days 1 predose, and Days 1 and 7 0-6, 6-12, and 12-24 hours post-dose

Secondary Outcomes (5)

• 24-Hour Intragastric pH Profile

  Day 1 and Day 7

• Total Amount of Serum Gastrin

  Predose Days 1 to 7, Day 7 24 hours post-dose, and Day 15

• Total Amount of Serum Pepsinogens I

  Predose Days 1 to 7, Day 7 24 hours post-dose, and Day 15

• Total Amount of Serum Pepsinogens II

  Predose Days 1 to 7, Day 7 24 hours post-dose, and Day 15

• Pepsinogens I/Pepsinogens II Ratio

  Predose Days 1 to 7, Day 7 24 hours post-dose, and Day 15

Study Arms (6)

TAK-438 10 mg

EXPERIMENTAL

TAK-438 10 mg, tablets, orally, once, daily, Days 1 to 7.

Drug: TAK-438

TAK-438 15 mg

EXPERIMENTAL

TAK-438 15 mg, tablets, orally, once, daily, Days 1 to 7.

Drug: TAK-438

TAK-438 20 mg

EXPERIMENTAL

TAK-438 20 mg, tablets, orally, once, daily, Days 1 to 7.

Drug: TAK-438

TAK-438 30 mg

EXPERIMENTAL

TAK-438 30 mg, tablets, orally, once, daily, Days 1 to 7.

Drug: TAK-438

TAK-438 40 mg

EXPERIMENTAL

TAK-438 40 mg, tablets, orally, once, daily, Days 1 to 7.

Drug: TAK-438

Placebo

PLACEBO COMPARATOR

TAK-438 placebo-matching tablets, orally, once, daily, Days 1 to 7.

Drug: TAK-438 Placebo

Interventions

TAK-438 DRUG

TAK-438 tablets

TAK-438 10 mg; TAK-438 15 mg; TAK-438 20 mg; TAK-438 30 mg; TAK-438 40 mg

TAK-438 Placebo DRUG

TAK-438 placebo-matching tablets

Placebo

Eligibility Criteria

• Age: 20 Years - 45 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy adult Japanese male volunteer.
• Is 20-45 years old inclusive, at time of giving consent.
• Is capable of understanding and complying with protocol requirements.
• Signs a written, informed consent form prior to the initiation of any study procedure.
• Weighs at least 50 kg and has a body mass index (BMI) of 18.5 to 25.0 kg/m\^2 inclusive at screening.
• Tests negative for hepatitis B surface antigen (HBs), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antigen-antibody and syphilis serum reaction test.
• The participant who the investigator or subinvestigator confirmed to be eligible to participate in this study based on results of the screening tests, and physical examination, physical findings, vital signs, electrocardiogram (ECG), clinical laboratory tests etc. from 3 days before dosing to before the start of dosing on Day 1 with the study drug.

You may not qualify if:

• Has undergone upper gastrointestinal resectioning or vagetomy.
• Is judged to have hypoacidity or anacidity.
• Presently has or a history of acid-related diseases (e.g., erosive esophagitis, duodenal ulcer, gastric ulcer, non-erosive esophagitis, Barrett's esophagitis or Zollinger-Ellison syndrome).
• Received H. pylori eradication treatment within 6 months prior to the start of treatment with the study drug.
• Presently has or has a history of hepatic disorder, renal disorder, cardiovascular system disease, blood disease, endocrine disease, metabolic disease, lung disease, gastrointestinal disease, nervous system disease, urological disease, immunological disease or mental illness that makes him not eligible to participate in this study.
• Presently has or has a history of hypersensitivity or allergy towards drugs or food.
• Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 5 years prior to the start of treatment with the study drug.
• Participant for whom it is difficult to collect blood from the peripheral veins.
• Has donated more than 200 mL of whole blood within 4 weeks (28 days) or more than 400 mL of whole blood within 12 weeks (84 days) prior to the start of treatment with the study drug.
• Has donated a total volume of more than 800 mL of whole blood within 52 weeks (364 days) prior to the start of treatment with the study drug.
• Has given plasma component and plaque component within 2 weeks (14 days) prior to the start of treatment with the study drug.
• Has used a prescription drug (including over-the counter drugs) within 4 weeks (28 days) prior to the start of treatment with the study drug.
• Has used vitamins, Chinese herbal remedies, or supplement (including St John's Wort, ginseng, kava kava, ginkgo biloba, melatonin) within 4 weeks (28 days) prior to the start of treatment with the study drug.
• Has ingested any foods or beverages containing grapefruit (juice or pulp), caffeine, alcohol within 72 hours prior to the start of treatment with the study drug.
• Administered another study drug within 16 weeks (112 days) prior to the start of treatment with this study drug.

Sponsors & Collaborators

• Takeda: lead

Related Publications (1)

• Jenkins H, Sakurai Y, Nishimura A, Okamoto H, Hibberd M, Jenkins R, Yoneyama T, Ashida K, Ogama Y, Warrington S. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015 Apr;41(7):636-48. doi: 10.1111/apt.13121. Epub 2015 Feb 23.

  PMID: 25707624 DERIVED

MeSH Terms

Interventions

1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine

Study Officials

• Medical Director Clinical Science

  Takeda

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 24, 2014
• First Posted: April 28, 2014
• Study Start: October 1, 2008
• Primary Completion: March 1, 2009
• Study Completion: March 1, 2009
• Last Updated: April 28, 2014

Record last verified: 2014-04